- New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment
- Additional £4.7m for new training facilities and an online learning platform to boost vaccine as well as cell and gene therapy skills
- New centre and skills vital for the UK’s ability respond to diseases like coronavirus, and potential future pandemics
The 2020 annual report released today presents Cell and Gene Therapy Catapult's achievements, collaborations and initiatives from the past year and their impact in enhancing growth, productivity and supporting the development and commercialisation of cell and gene therapies.
The collaboration will see Achilles Therapeutics expand their manufacturing footprint at the CGT Catapult manufacturing centre to supply clinical trials of their novel T cell therapy products. Onboarding has begun into one of the newly operational modules at the state-of-the-art facility.
MicrofluidX announces it has raised £1.4m in seed funding to develop its novel cell bioprocessing technology, utilising microfluidics to tackle the challenges associated with bioprocessing for cell and gene therapy.
Fieldfisher are delighted to announce that their pan-European Life Sciences sector group have mobilised to show support for life science companies contributing efforts towards global pandemic COVID-19.
Governments across the world, healthcare providers and device manufacturers can now request a free of charge licence to the design and manufacturing files of a breathing aid developed by UCL, UCLH and Mercedes-AMG High Performance Powertrains (Mercedes-AMG HPP) to support healthcare systems preparing for the Covid-19 pandemic.